NO20051273L - Piperidinylforbindelser som selektivt binder integriner - Google Patents
Piperidinylforbindelser som selektivt binder integrinerInfo
- Publication number
- NO20051273L NO20051273L NO20051273A NO20051273A NO20051273L NO 20051273 L NO20051273 L NO 20051273L NO 20051273 A NO20051273 A NO 20051273A NO 20051273 A NO20051273 A NO 20051273A NO 20051273 L NO20051273 L NO 20051273L
- Authority
- NO
- Norway
- Prior art keywords
- selectively bind
- piperidinyl compounds
- bind integrins
- compounds
- piperidinyl
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title abstract 3
- 108010044426 integrins Proteins 0.000 title abstract 3
- 125000003386 piperidinyl group Chemical group 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Det beskrives piperidinylforbindelser med formel (I) og (II) der W, R2, Z og q er som beskrevet. Forbindelsene med formel (I) og (II) binder selektivt integrinreseptorer og egner seg derfor for behandling av integrin-medierte lidelser.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40423902P | 2002-08-16 | 2002-08-16 | |
PCT/US2003/025782 WO2004020435A1 (en) | 2002-08-16 | 2003-08-15 | Piperidinyl compounds that selectively bind integrins |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20051273L true NO20051273L (no) | 2005-05-10 |
NO332036B1 NO332036B1 (no) | 2012-06-04 |
Family
ID=31978252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20051273A NO332036B1 (no) | 2002-08-16 | 2005-03-11 | Piperidinylforbindelser som selektivt binder integriner og sammensetninger derav |
Country Status (24)
Country | Link |
---|---|
US (1) | US20040077684A1 (no) |
EP (1) | EP1539739B1 (no) |
JP (1) | JP4554364B2 (no) |
KR (1) | KR20050031464A (no) |
CN (1) | CN100506815C (no) |
AR (1) | AR041010A1 (no) |
AT (1) | ATE489378T1 (no) |
AU (2) | AU2003259891A1 (no) |
BR (1) | BR0313534A (no) |
CA (1) | CA2496127C (no) |
CR (1) | CR7692A (no) |
CY (1) | CY1111194T1 (no) |
DE (1) | DE60335118D1 (no) |
DK (1) | DK1539739T3 (no) |
ES (1) | ES2355139T3 (no) |
IL (1) | IL166534A (no) |
MX (1) | MXPA05001859A (no) |
NO (1) | NO332036B1 (no) |
PL (1) | PL219749B1 (no) |
PT (1) | PT1539739E (no) |
RU (1) | RU2333210C2 (no) |
SI (1) | SI1539739T1 (no) |
UA (1) | UA83467C2 (no) |
WO (1) | WO2004020435A1 (no) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
US7351711B2 (en) | 2003-07-31 | 2008-04-01 | Janssen Pharmaceutical, N.V. | Tricyclic indanyls as integrin inhibitors |
DK1734996T3 (da) * | 2004-04-02 | 2013-06-10 | Univ California | Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin |
CA2590386A1 (en) * | 2004-12-30 | 2006-07-06 | Cinvention Ag | Combination comprising an agent providing a signal, an implant material and a drug |
WO2006073314A1 (en) * | 2005-01-06 | 2006-07-13 | Ge Healthcare As | Optical imaging |
US20080058922A1 (en) * | 2006-08-31 | 2008-03-06 | Cardiac Pacemakers, Inc. | Methods and devices employing vap-1 inhibitors |
US8636995B2 (en) * | 2006-08-31 | 2014-01-28 | Cardiac Pacemakers, Inc. | Methods and devices to regulate stem cell homing |
US8372399B2 (en) * | 2006-08-31 | 2013-02-12 | Cardiac Pacemakers, Inc. | Bispecific antibodies and agents to enhance stem cell homing |
EP2178858B1 (en) * | 2007-08-02 | 2011-12-28 | Recordati Ireland Limited | Novel heterocyclic compounds as mglu5 antagonists |
JP2011519340A (ja) * | 2007-10-30 | 2011-07-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換アルカン酸調製のためのエナンチオ選択的プロセスこの米国特許正規出願は、2007年10月30日に提出された米国特許仮出願第61/001,004号、及び2008年2月29日に提出された米国特許仮出願第61/067,842号の権利を主張する。 |
JP5637855B2 (ja) * | 2007-11-08 | 2014-12-10 | ザ ジェネラル ホスピタル コーポレイション | 蛋白尿症の治療のための方法及び組成物 |
KR101752515B1 (ko) | 2009-07-24 | 2017-06-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Avb5 인테그린과 결부된 질환의 치료 및 예방을 위한 방법 및 조성물 |
HUE063437T2 (hu) | 2013-09-24 | 2024-01-28 | Fujifilm Corp | Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény |
CA3037369A1 (en) | 2016-09-18 | 2018-03-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Yap1 inhibitors that target the interaction of yap1 with oct4 |
US10717736B2 (en) * | 2016-11-08 | 2020-07-21 | Bristol-Myers Squibb Company | Pyrrole amides as alpha V integrin inhibitors |
CA3042684A1 (en) * | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Azole amides and amines as .alpha.v integrin inhibitors |
US20180244648A1 (en) | 2017-02-28 | 2018-08-30 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
SG11202008854TA (en) | 2018-03-14 | 2020-10-29 | H Lee Moffitt Cancer Center And Research Institute Inc | Yap1 inhibitors that target the interaction of yap1 with oct4 |
CR20210109A (es) | 2018-08-29 | 2021-06-24 | Morphic Therapeutic Inc | INHIBICIÓN DE LA INTEGRINA av ß6 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN148482B (no) * | 1977-06-03 | 1981-03-07 | Pfizer | |
ATE239506T1 (de) * | 1992-03-05 | 2003-05-15 | Univ Texas | Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren |
US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
US5902795A (en) * | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
US5340798A (en) * | 1992-10-14 | 1994-08-23 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5753659A (en) * | 1993-03-29 | 1998-05-19 | Zeneca Limited | Heterocyclic compouds |
US5700801A (en) * | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
DE19613933A1 (de) * | 1996-04-06 | 1997-10-09 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
US5919792A (en) * | 1996-10-30 | 1999-07-06 | Merck & Co., Inc. | Integrin antagonists |
WO1999030713A1 (en) * | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
US6211191B1 (en) * | 1997-12-17 | 2001-04-03 | Merck & Co., Inc. | Integrin receptor antagonists |
CA2333647A1 (en) * | 1998-06-29 | 2000-01-06 | Dupont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
CA2372053C (en) * | 1999-04-28 | 2008-09-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
-
2003
- 2003-08-15 RU RU2005104115/04A patent/RU2333210C2/ru not_active IP Right Cessation
- 2003-08-15 DE DE60335118T patent/DE60335118D1/de not_active Expired - Lifetime
- 2003-08-15 UA UAA200502396A patent/UA83467C2/uk unknown
- 2003-08-15 KR KR1020057001657A patent/KR20050031464A/ko not_active Application Discontinuation
- 2003-08-15 AT AT03791686T patent/ATE489378T1/de active
- 2003-08-15 CA CA2496127A patent/CA2496127C/en not_active Expired - Fee Related
- 2003-08-15 PT PT03791686T patent/PT1539739E/pt unknown
- 2003-08-15 WO PCT/US2003/025782 patent/WO2004020435A1/en active Application Filing
- 2003-08-15 US US10/641,964 patent/US20040077684A1/en not_active Abandoned
- 2003-08-15 AU AU2003259891A patent/AU2003259891A1/en not_active Abandoned
- 2003-08-15 CN CNB038240904A patent/CN100506815C/zh not_active Expired - Fee Related
- 2003-08-15 EP EP03791686A patent/EP1539739B1/en not_active Expired - Lifetime
- 2003-08-15 DK DK03791686.3T patent/DK1539739T3/da active
- 2003-08-15 AR ARP030102976A patent/AR041010A1/es unknown
- 2003-08-15 SI SI200331951T patent/SI1539739T1/sl unknown
- 2003-08-15 JP JP2004532905A patent/JP4554364B2/ja not_active Expired - Fee Related
- 2003-08-15 BR BR0313534-9A patent/BR0313534A/pt not_active IP Right Cessation
- 2003-08-15 PL PL375562A patent/PL219749B1/pl unknown
- 2003-08-15 ES ES03791686T patent/ES2355139T3/es not_active Expired - Lifetime
- 2003-08-15 MX MXPA05001859A patent/MXPA05001859A/es active IP Right Grant
-
2005
- 2005-01-27 IL IL166534A patent/IL166534A/en not_active IP Right Cessation
- 2005-02-15 CR CR7692A patent/CR7692A/es unknown
- 2005-03-11 NO NO20051273A patent/NO332036B1/no not_active IP Right Cessation
-
2010
- 2010-10-25 AU AU2010236002A patent/AU2010236002B2/en not_active Ceased
-
2011
- 2011-02-09 CY CY20111100158T patent/CY1111194T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1539739A1 (en) | 2005-06-15 |
DK1539739T3 (da) | 2011-03-07 |
SI1539739T1 (sl) | 2011-04-29 |
DE60335118D1 (de) | 2011-01-05 |
CR7692A (es) | 2009-01-14 |
AU2003259891A1 (en) | 2004-03-19 |
CA2496127A1 (en) | 2005-02-16 |
PT1539739E (pt) | 2011-01-05 |
BR0313534A (pt) | 2005-07-12 |
AU2010236002B2 (en) | 2012-05-03 |
MXPA05001859A (es) | 2005-06-03 |
PL219749B1 (pl) | 2015-07-31 |
EP1539739B1 (en) | 2010-11-24 |
RU2333210C2 (ru) | 2008-09-10 |
AR041010A1 (es) | 2005-04-27 |
ATE489378T1 (de) | 2010-12-15 |
NO332036B1 (no) | 2012-06-04 |
IL166534A (en) | 2012-05-31 |
ES2355139T3 (es) | 2011-03-23 |
WO2004020435A1 (en) | 2004-03-11 |
IL166534A0 (en) | 2006-01-15 |
UA83467C2 (uk) | 2008-07-25 |
US20040077684A1 (en) | 2004-04-22 |
CY1111194T1 (el) | 2015-06-11 |
CN1688572A (zh) | 2005-10-26 |
CA2496127C (en) | 2012-05-29 |
RU2005104115A (ru) | 2005-08-27 |
CN100506815C (zh) | 2009-07-01 |
AU2010236002A1 (en) | 2010-11-11 |
JP2005539049A (ja) | 2005-12-22 |
JP4554364B2 (ja) | 2010-09-29 |
KR20050031464A (ko) | 2005-04-06 |
PL375562A1 (en) | 2005-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20051273L (no) | Piperidinylforbindelser som selektivt binder integriner | |
NO20053647L (no) | Pyrazolopyridinderivater | |
RS20050112A (en) | Pyrrolidinedione substituted piperidine-phtalazones as pde4 | |
CY1113054T1 (el) | Παραγωγα διαμινης | |
CY1114284T1 (el) | Σουλφονυλοπυρρολες ως hdac αναστολεις | |
NO20064288L (no) | Tetraazabenzo(E)azulen-derivater og angaloger derav | |
IL185275A0 (en) | N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same | |
CY1112780T1 (el) | Νεα σουλφονυλοπυρρολια ως αναστολεις της ηdac | |
NO20050828L (no) | lndol-3-svovelderivater | |
WO2004018449A8 (en) | Piperidine-derivatives as pde4 inhibitors | |
NO20062629L (no) | Oksazolderivater av tetrackliner | |
NO20063576L (no) | 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes | |
NO20054787L (no) | Indenderivater som farmasotiske midler | |
DE60324544D1 (de) | Muskarin antagonisten | |
NO20064351L (no) | Caspaseinhibitorer og anvendelser derav | |
NO20061789L (no) | Aminopyridinderivater som induserbare NO-syntaseinhibitorer | |
WO2005009392A3 (en) | Dihydropyrimidone inhibitors of calcium channel function | |
NO20052994L (no) | Nye fosforamidderivater. | |
TR200201128T2 (tr) | PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri. | |
DE602004014628D1 (de) | Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren | |
NO20050885L (no) | Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre | |
NO20055749L (no) | Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer | |
AP2001002188A0 (en) | 5HT1 antagonists for antidepressant therapy. | |
NO20081529L (no) | Naftyridinderivater | |
DE60311000D1 (de) | Indolderivate und deren verwendung als 5-ht liganden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |